UK-based Emergex Vaccines has secured a research and development (R&D) facility and hired a chief scientific officer (CSO).
The company’s stated aim is to pioneer a new approach to vaccine development in order to address some of the world’s most immediate health threats including flaviviruses, such as dengue fever and zika, as well as filoviruses, including Ebola and Marburg viruses, and seasonal and pandemic influenza.
"As well as being designed to provide long-lasting immunity and to be easily administered, Emergex’s vaccines can be rapidly-produced for testing and then cost-effectively manufactured"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze